Share on Facebook
Share on Twitter
Share on LinkedIn

U.S. regulators halted Amgen Inc. (AMGN)’s pediatric clinical trials of the kidney drug Sensipar after a 14-year-old patient died.

Sensipar, approved in adults in 2004, was being tested for effectiveness and safety in children younger than 18 years old, the Food and Drug Administration said today in a statement. The FDA said it hasn’t concluded whether Sensipar had a role in the death and will make recommendations when its review is complete.

Click here to read more.